Meta-analysis of diagnostic test accuracy studies is an increasingly pivotal approach in evidence-based medicine, enabling the synthesis of data from multiple investigations to assess the performance ...
SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback